We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Appoints New Pharma Unit Head, Gives Other Updates
Read MoreHide Full Article
Swiss pharma giant Novartis (NVS - Free Report) announced that Marie-France Tschudin has been appointed president of the Pharmaceuticals business unit. The appointment comes as Paul Hudson, who was heading the unit so far, is leaving the company and joining Sanofi (SNY - Free Report) . Marie-France is currently the president of Advanced Accelerator Applications (AAA), a Novartis company,
Marie-France joined the company in January 2017 and was working with biotech major Celgene Corporation in a variety of positions earlier.
The change in leadership comes at a crucial time for Novartis, when it is looking to streamline its business and focus on legacy drug business, going forward.
Earlier, AAA announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of LysaKare 25g/25g solution for reduction of renal (kidney) radiation exposure in adults during peptide-receptor radionuclide therapy (PRRT) with Lutathera, the first PRRT ever approved by the European Commission. The European Commission will review the CHMP opinion and is expected to deliver its final decision within three months.
Lutathera was approved in September 2017 for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.
Novartis also announced new early stage histology data in kidney transplantation on pipeline candidate, iscalimab, at the American Transplant Congress (ATC).
Data show that 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus. The findings, although in a limited number of patients, are to be confirmed in an ongoing phase IIb trial.
Novartis’ share price has increased 2.2% in a year compared with the industry's 0.6% growth.
The company has restructured the business to focus on becoming a core drug-focused company, powered by data and digital technologies, given the challenging business conditions. The generic division, Sandoz, continues to face pricing pressure in the United States.
Zacks Rank & Stock to Consider
Novartis currently carries a Zacks Rank #4 (Sell).
Bristol-Myers’ earnings per share estimates have increased from $4.78 to $5.03 for 2020 in the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Novartis Appoints New Pharma Unit Head, Gives Other Updates
Swiss pharma giant Novartis (NVS - Free Report) announced that Marie-France Tschudin has been appointed president of the Pharmaceuticals business unit. The appointment comes as Paul Hudson, who was heading the unit so far, is leaving the company and joining Sanofi (SNY - Free Report) . Marie-France is currently the president of Advanced Accelerator Applications (AAA), a Novartis company,
Marie-France joined the company in January 2017 and was working with biotech major Celgene Corporation in a variety of positions earlier.
The change in leadership comes at a crucial time for Novartis, when it is looking to streamline its business and focus on legacy drug business, going forward.
Earlier, AAA announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of LysaKare 25g/25g solution for reduction of renal (kidney) radiation exposure in adults during peptide-receptor radionuclide therapy (PRRT) with Lutathera, the first PRRT ever approved by the European Commission. The European Commission will review the CHMP opinion and is expected to deliver its final decision within three months.
Lutathera was approved in September 2017 for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.
Novartis also announced new early stage histology data in kidney transplantation on pipeline candidate, iscalimab, at the American Transplant Congress (ATC).
Data show that 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus. The findings, although in a limited number of patients, are to be confirmed in an ongoing phase IIb trial.
Novartis’ share price has increased 2.2% in a year compared with the industry's 0.6% growth.
The company has restructured the business to focus on becoming a core drug-focused company, powered by data and digital technologies, given the challenging business conditions. The generic division, Sandoz, continues to face pricing pressure in the United States.
Zacks Rank & Stock to Consider
Novartis currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the large-cap pharma space is Bristol-Myers Squibb Co. (BMY - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bristol-Myers’ earnings per share estimates have increased from $4.78 to $5.03 for 2020 in the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>